Founder, chairman and managing director wants to make Biocon, Ltd. one of the top 10 biotech companies in 2015. The company was engaged in a low-risk enzymes and generic drugs for many years. In order for the company to grow, the chairman believes that Biocon must enter a risky business discovery and development of drugs. Without making a major investment in new opportunities, it can not become a top 10 biotechnology firms. "Hide
by Alison Conrad, Charlene L. Nicholls-Nixon, Ramasastry Chandrasekhar Source: Richard Ivey School of Business Foundation 15 pages. Publication Date: September 13, 2006. Prod. #: 906M70-PDF-ENG
Related Case Solutions & Analyses:
Microsofts Go-to-market Strategy for Azure in India
Impulsesoft – Music in the Air
Coaching for Exceptional Performance Workshop: Senior Associate Institutional Investor Relations Kelly Tan
Horseshoe Resort
We Have a Terrible Tragedy Here (C)
Weathering the Storm: Awarding an Honorary Degree to Canadas Pioneer Abortion Doctor (A)
Twilight Acre Farms Limited
United Grain Growers Limited (B): The ADM Alternative
MessageTech Inc.
Hutchison Whampoa Ltd.: The Capital Structure Decision
